Aeglea Bio Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Spyre Therapeutics

11/08/2023 12:54

* Aeglea Bio Therapeutics Inc  AGLE.OQ  reported a quarterly
adjusted loss of $1.66​​ per share for the quarter ended in
June. The mean expectation of two analysts for the quarter was
for a loss of 18 cents per share.
    * Revenue rose 10.1% to $688.00 thousand from a year ago;
analysts
expected zero. 
    * Aeglea Bio Therapeutics Inc's reported EPS for the quarter
was a
loss of $2.27​.
    * The mean earnings estimate of analysts had fallen by
about 38.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aeglea Bio Therapeutics Inc shares had risen by 16.5% this
quarter and gained 16.6% so far this year.
    * The company reported a quarterly loss of $217.08 million.
    * Wall Street's median 12-month price target for Aeglea Bio
Therapeutics Inc is $0.90 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 11 at 11:54 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.18          -1.66          Missed
 Mar. 31 2023      -0.18          -0.20          Missed
 Dec. 31 2022      -0.20          -0.18          Beat
 Sep. 30 2022      -0.23          -0.19          Beat